Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating

Retrieved on: 2022-10-10 11:46:10

Tags for this article:

Medicine

Medical specialties

Tumor-infiltrating lymphocytes

Melanoma

Programmed cell death protein 1

Cancer immunotherapy

Gene therapy

Iovance Biotherapeutics Inc.

Click the tags to see associated articles and topics

Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating. View article details on hiswai:

Excerpt

(NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that the first patient was dosed, ...

Article found on: www.bakersfield.com

View Original Article